top of page
Search

A2A co-founded biomea Fusion raises $56M

  • Writer: A2A Pharma
    A2A Pharma
  • Jan 13, 2021
  • 1 min read

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of a $56 million Series A financing today. The syndicate is led by Cormorant Asset Management with participation from Boxer Capital of Tavistock Group, Janus Henderson Investors, Rock Springs Capital, RTW Investments, LP, Aisling Capital, Point Sur Investors, Logos Capital and Clifton Capital.


 
 
 

Recent Posts

See All

Comments


bottom of page